Video

Dr. Michael Lim on Toxicities of Checkpoint Inhibitors

Author(s):

Michael Lim, MD, Director of Brain Tumor Immunotherapy, Associate Professor of Neurosurgery, Johns Hopkins Medicine, discusses toxicities associated with checkpoint inhibitors for the treatment of glioblastoma.

Michael Lim, MD, director of Brain Tumor Immunotherapy, associate professor of Neurosurgery, Johns Hopkins Medicine, discusses toxicities associated with checkpoint inhibitors for the treatment of glioblastoma.

Checkpoint inhibitors have the potential to improve quality of life and tumor control for patients with glioblastoma, says Lim.

However, because checkpoint inhibitors release the breaks on the immune system they can induce autoimmune disorders. The two most concerning disorders that can result from the use of checkpoint inhibitors are colitis and nemunaitis, which can both be life threatening, says Lim.

To avoid serious complications from checkpoint inhibitors, oncologists need to monitor patients closely and act early, says Lim.

Related Videos
Omid Hamid, MD
Marlana M. Orloff, MD
Mark Faries, MD
Rene Y. McNall-Knapp, MD, pediatric hematologist-oncologist, Jimmy Everest Center, Oklahoma Children’s Hospital OU Health; professor, Department of Pediatrics, University of Oklahoma Health Sciences Center
Howard Colman, MD, PhD, Jan M. Huntsman Presidential Professor, Department of Neurosurgery, member, Brain Tumor Research Team, and leader, Center for Neurologic Cancers, Huntsman Cancer Institute, University of Utah
FRCSI, FRCSEd, medical director, Thoracic Cancer Program, and associate executive director, AdventHealth Cancer Institute
Benjamin P. Levy, MD, clinical director, Medical Oncology, Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital; and associate professor, oncology, Johns Hopkins University School of Medicine
Russell Hales, MD, director, Thoracic Oncology Multidisciplinary Program, associate professor, clinical radiation oncology and molecular radiation sciences, and director, thoracic multidisciplinary clinic, John Hopkins University School of Medicine
Estelamari Rodriguez, MD, MPH, associate director, Community Outreach – Thoracic Oncology, Sylvester Comprehensive Cancer Center
Kathleen N. Moore, MD, MS